Business UpdateJun 17, 2026, 07:34 AM
Nexentis' MitoCareX Expands Drug Discovery via SLC Protein Analysis
AI Summary
Nexentis Technologies Inc.'s subsidiary, MitoCareX Bio Ltd., announced the completion of a broad structural analysis of human SLC transport proteins. This work expands the application of its proprietary MITOLINE® platform beyond mitochondrial SLC25 carrier proteins, identifying additional non-mitochondrial SLC proteins amenable to MITOLINE-enabled structural modeling. MitoCareX intends to explore using these 3D models for virtual screening, aiming to broaden its small-molecule discovery efforts into new disease-relevant transport proteins.
Key Highlights
- MitoCareX completed a broad structural analysis of human SLC transport proteins.
- The analysis expands the MITOLINE® platform's application beyond mitochondrial SLC25 carriers.
- Identified additional non-mitochondrial SLC proteins compatible with MITOLINE® for 3D modeling.
- MitoCareX plans to use MITOLINE®-derived 3D models for virtual screening of new SLC targets.
- The company aims to expand small-molecule discovery efforts into additional disease-relevant proteins.
- Nexentis also invests in four solar projects across three EU countries via Solterra Renewable Energy.
Price Impact
More from NXTS